Loading news...
Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) shares saw unusually-high trading volume on Friday. Approximately 16,181,427 shares changed hands during mid-day trading, an increase of 257% from the previous session's volume of 4,538,231 shares.The stock last traded at $13.9850 and had previously closed at $13.97. Analysts Set New Price Targets A number of
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Analyst Recommendations This is a breakdown of recent
Cibc World Market Inc. reduced its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 39.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,250 shares of the company's stock after selling 99,750 shares during the period. Cibc World Market Inc.
Shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) have earned a consensus recommendation of "Reduce" from the nine analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and eight have issued a hold recommendation on the company. The average 12 month price target among
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences, Inc. (NasdaqGS: VTYX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Ventyx will receive $14.00 in cash for each share of Ventyx that they own. KSF is seeking to determine whether this consideration and the process that led to i.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Shareholders should contact the firm as there may be limited time to enforce your rights. Shareholders should contact the firm as there may be limited time to enforce your rights.
BALA CYNWYD, Pa. , Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith.
Shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) have been given a consensus rating of "Reduce" by the nine analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year target price among
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Cwm LLC decreased its stake in shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 66.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,279 shares of the company's stock after selling 37,866 shares during the quarter. Cwm LLC's holdings in
Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 7,294,699 shares, a growth of 19.8% from the December 15th total of 6,089,007 shares. Approximately 12.5% of the shares of the stock are sold short. Based
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Ventyx Biosciences, Inc. ("Ventyx") (NASDAQ: VTYX), resulting from allegations of providing potentially misleading business information to the investing public.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.